PURPOSE: We investigated the role of genetic, physiological, environmental, and epigenetic factors in regulating CYP2A6 expression and nicotine metabolism. METHODS: Human livers (n = 67) were genotyped for CYP2A6 alleles and assessed for nicotine metabolism and CYP2A6 expression (mRNA and protein). In addition, a subset of livers (n = 18), human cryopreserved hepatocytes (n = 2), and HepG2 cells were used for DNA methylation analyses. RESULTS: Liver samples with variant CYP2A6 alleles had significantly lower CYP2A6 protein expression, nicotine C-oxidation activity, and affinity for nicotine. Female livers had significantly higher CYP2A6 protein and mRNA expression compared to male livers. Livers exposed to dexamethasone and phenobarbital had higher CYP2A6 expression and activity, however the difference was not statistically significant. Age and DNA methylation status of the CpG island and a regulatory site were not associated with altered CYP2A6. CONCLUSIONS: We identified genotype, gender, and exposure to inducers as sources of variation in CYP2A6 expression and activity, but much variation remains to be accounted for.
PURPOSE: We investigated the role of genetic, physiological, environmental, and epigenetic factors in regulating CYP2A6 expression and nicotine metabolism. METHODS:Human livers (n = 67) were genotyped for CYP2A6 alleles and assessed for nicotine metabolism and CYP2A6 expression (mRNA and protein). In addition, a subset of livers (n = 18), human cryopreserved hepatocytes (n = 2), and HepG2 cells were used for DNA methylation analyses. RESULTS: Liver samples with variant CYP2A6 alleles had significantly lower CYP2A6 protein expression, nicotine C-oxidation activity, and affinity for nicotine. Female livers had significantly higher CYP2A6 protein and mRNA expression compared to male livers. Livers exposed to dexamethasone and phenobarbital had higher CYP2A6 expression and activity, however the difference was not statistically significant. Age and DNA methylation status of the CpG island and a regulatory site were not associated with altered CYP2A6. CONCLUSIONS: We identified genotype, gender, and exposure to inducers as sources of variation in CYP2A6 expression and activity, but much variation remains to be accounted for.
Authors: Nael Al Koudsi; Jill C Mwenifumbo; Edward M Sellers; Neal L Benowitz; Gary E Swan; Rachel F Tyndale Journal: Eur J Clin Pharmacol Date: 2006-04-28 Impact factor: 2.953
Authors: Andrew Parkinson; Daniel R Mudra; Cory Johnson; Anne Dwyer; Kathleen M Carroll Journal: Toxicol Appl Pharmacol Date: 2004-09-15 Impact factor: 4.219
Authors: Ming-Fen Ho; Cristina Correia; James N Ingle; Rima Kaddurah-Daouk; Liewei Wang; Scott H Kaufmann; Richard M Weinshilboum Journal: Biochem Pharmacol Date: 2018-04-03 Impact factor: 5.858
Authors: Meghan J Chenoweth; Andy Z X Zhu; Lisa Sanderson Cox; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale Journal: Pharmacogenet Genomics Date: 2014-03 Impact factor: 2.089
Authors: Andy Z X Zhu; Matthew J Binnington; Caroline C Renner; Anne P Lanier; Dorothy K Hatsukami; Irina Stepanov; Clifford H Watson; Connie S Sosnoff; Neal L Benowitz; Rachel F Tyndale Journal: Carcinogenesis Date: 2012-10-01 Impact factor: 4.944
Authors: Julie-Anne Tanner; Andy Z Zhu; Katrina G Claw; Bhagwat Prasad; Viktoriya Korchina; Jianhong Hu; HarshaVardhan Doddapaneni; Donna M Muzny; Erin G Schuetz; Caryn Lerman; Kenneth E Thummel; Steven E Scherer; Rachel F Tyndale Journal: Pharmacogenet Genomics Date: 2018-01 Impact factor: 2.089
Authors: Andy Z X Zhu; Caroline C Renner; Dorothy K Hatsukami; Gary E Swan; Caryn Lerman; Neal L Benowitz; Rachel F Tyndale Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-01-31 Impact factor: 4.254